When President Bush signed Project BioShield into law in July, he said he was immediately making $5.6 billion available to counter such anticipated threats as smallpox genetically engineered to render current vaccines useless.But the expected flood of contracts never materialized. Project BioShield was supposed to jump-start a national security renaissance in the biotechnology and pharmaceutical industries by guaranteeing contracts to make drugs for combatting potential bioweapons. But all the law has done so far is to generate indifference or frustration among biodefense contractors, industry executives and experts say. Most are snubbing the program because of liability and intellectual property issues and confusion over what the government wants.Full Story
About OODA Analyst
OODA is comprised of a unique team of international experts capable of providing advanced intelligence and analysis, strategy and planning support, risk and threat management, training, decision support, crisis response, and security services to global corporations and governments.